Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

odanacatib

- PMLiVE

Novartis cancer pill makes it onto UK early access list

Joins Merck’s melanoma drug Keytruda for the MHRA’s accelerated review programme 

- PMLiVE

Novartis steps up its efforts in immuno-oncology

Dedicated R&D unit created alongside $750m collaboration with Aduro

- PMLiVE

UK to pay for GSK’s MenB vaccine after year’s delay

British firm says the deal offers ‘fair value’ to the NHS

- PMLiVE

Icelandic genome study yields new disease genes

Nature Medicine study focuses on the probability of developing Alzheimer’s

- PMLiVE

Pricing pressures preventing UK access to MenB vaccine

GlaxoSmithKline’s Bexsero will need a dramatic price cut to gain NHS entry

- PMLiVE

UCB: Patient centricity should move a business forward

Pharma may become obsolete if it does not include the patient voice, says Lode Dewulf

- PMLiVE

Baxter haemophilia drug clears phase III trial

BAX 817 shown to resolve more than 90% of acute bleeds

- PMLiVE

UCB plans epilepsy ‘hackathon’ to develop new digital tools

Aims to attract developers, designers and digital experts to Hack Epilepsy

- PMLiVE

Cosentyx has big impact on psoriasis, says Novartis

New data shows it to achieve clear or almost clear skin

- PMLiVE

NICE set to back Novartis’ Xolair for skin condition CSU

Issues final draft guidance on the treatment's use as an add-on for chronic spontaneous urticaria

- PMLiVE

FDA approves first biosimilar

Novartis’ Sandoz unit gains new licence for Neupogen copycat

EU flag

New cancer meds and drug extensions top CHMP recommendations

Drugs for rare disease, oncology and diabetes top regulator’s endorsements

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links